Immunomedics Announces Presentations at Upcoming Conferences

Immunomedics Announces Presentations at Upcoming Conferences

MORRIS PLAINS, N.J., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc.
(Nasdaq:IMMU), a biopharmaceutical company primarily focused on the
development of monoclonal antibody-based products for the targeted treatment
of cancer, autoimmune and other serious diseases, today announced that the
Company will be making multiple presentations at 3 upcoming scientific and
medical conferences.

At the World ADC San Francisco 2013, scheduled for October 14-17, 2013 in San
Francisco, CA, Cynthia L. Sullivan, President and Chief Executive Officer,
will present "The Growth Potential for using ADCs: Diverse Cancer Types,"
including the IMMU-130, IMMU-132 and IMMU-110 program descriptions, during the
Commercial Leader's Day session on Monday, October 14, at 9:30 a.m. In
addition, Dr. David M. Goldenberg, Chairman, Chief Scientific Officer, and
Chief Medical Officer, will report "First Clinical Results of SN-38 ADCs in
Solid Tumor Therapy" in the Plenary Session: Early Clinical Trial Results on
Wednesday, October 16, at 4:30 p.m.

The Company and its collaborators will present 6 studies at the 26^th Annual
Congress of the European Association of Nuclear Medicine to be held in Lyon,
France, from October 19-23, 2013. The schedule and meeting places for the
presentations, together with the abstract number and session title, are listed

  o"Preclinical evaluation of Al^18F- and ^68Ga-labeled GRPR-antagonist for
    PET imaging of gastrin-releasing peptide receptor expression in prostate
    cancer" [Abstract No. OP060, Oral Session Title: Radiopharmaceuticals &
    Radiochemistry & Dosimetry: PET Radiopharmaceuticals, Sunday, October 20,
    11:41 a.m. – 11:52 a.m., Room: Rhône 3A/3B]

  o"SPECT/fluorescence dual-modality imaging of carcinoembryonic
    antigen-expressing tumors: a pretargeting study" [Abstract No. OP261, Oral
    Session Title: Featured - Molecular & Multimodality Imaging: Optical
    Imaging, Monday, October 21, 12:29 p.m. – 12:40 p.m., Room: Auditorium

  o"A Phase Ιb study of fractionated ^90Υ-clivatuzumab tetraxetan in patients
    with metastatic pancreatic cancer after ≥ 2 prior therapies" [Abstract No.
    OP670, Oral Session Title: Radionuclide Therapy & Dosimetry: Miscellaneous
    Therapy, Wednesday, October 23, 8:00 a.m. – 8:11 a.m., Room: Gratte-Ciel

  o"Radioimmunotherapy (RAIT) with anti-CD22 ^90Y-epratuzumab in adults with
    refractory or relapsed CD22+ ALL: preliminary results of a phase I/II
    study" [Abstract No. OP675, Oral Session Title: Radionuclide Therapy &
    Dosimetry: Miscellaneous Therapy, Wednesday, October 23, 8:55 a.m. – 9:06
    a.m., Room: Gratte-Ciel 1/2/3]

  o"Pharmacokinetics of yttrium-90-labeled epratuzumab in the consolidation
    radioimmunotherapy of non-Hodgkin's lymphoma" [Abstract No. P400, Poster
    Session Title: Therapy & Clinical Trials: Radioisotope Therapy -
    Miscellaneous, Sunday, October 20, 4:00 p.m. – 4:30 p.m., Room: Poster
    Exhibition Area]

  o"Anti-CEA antibody fragments labeled with [^18F]AlF for PET imaging of
    CEA-expressing tumors" [Abstract No. PW138, Poster Session Title: Poster
    Walk 14 - Radiopharmaceuticals & Radiochemistry & Dosimetry: Antibodies &
    Peptides, Tuesday, October 22, 9:15 a.m. – 9:20 a.m., Room:Poster
    Exhibition Area]

Finally, at the AACR-NCI-EORTC International Conference on Molecular Targets
and Cancer Therapeutics in Boston, MA, from October 19-23, 2013, a poster on
"Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2
antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial
cancers: Phase I clinical experience" will be presented in Poster Session C:
Clinical Trials 3 on Tuesday, October 22, at 12:30 p.m. - 3:00 p.m. in Exhibit
Hall C-D.

"These conferences provide the Company with opportunities to describe the
progress being made with many of its advanced products involving drug and
radionuclide conjugates being studied for the therapy or improved imaging of
advanced cancers," commented Cynthia L. Sullivan, President and Chief
Executive Officer. She added, "These include our antibody-drug conjugates
(ADCs) at two conferences, our novel immunoPET constructs using fluorine-18,
and also advances in the therapy of lymphomas and leukemias with our
^90Y-labeled epratuzumab."

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused
on the development of monoclonal antibody-based products for the targeted
treatment of cancer, autoimmune and other serious diseases.We have developed
a number of advanced proprietary technologies that allow us to create
humanized antibodies that can be used either alone in unlabeled or "naked"
form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or
toxins, in each case to create highly targeted agents.Using these
technologies, we have built a pipeline of therapeutic product candidates that
utilize several different mechanisms of action.Our lead product candidate,
epratuzumab, is currently in two Phase III clinical trials in lupus. In
oncology, we are planning to launch a Phase III pivotal trial for clivatuzumab
labeled with a radioisotope in advanced pancreatic cancer patients. Other
solid tumor therapeutics in Phase II clinical development include 2
antibody-drug conjugates, labetuzumab-SN-38 (IMMU-130) and hRS7-SN-38
(IMMU-132).We also have a majority ownership in IBC Pharmaceuticals, Inc.,
which is developing a novel DOCK-AND-LOCK™ (DNL™) method with us for making
fusion proteins and multifunctional antibodies. DNL™ is being used
particularly to make bispecific antibodies targeting cancers and infectious
diseases as a T-cell redirecting immunotherapy, as well as bispecific
antibodies for next-generation cancer and autoimmune disease therapies. We
believe that our portfolio of intellectual property, which includes
approximately 230 active patents in the United States and more than 400
foreign patents, protects our product candidates and technologies.Our
strength in intellectual property has resulted in the top-10 ranking in the
2012 IEEE Spectrum Patent Power Scorecards in the Biotechnology and
Pharmaceuticals category.For additional information on us, please visit our
website at The information on our website does not,
however, form a part of this press release.

This release, in addition to historical information, may contain
forward-looking statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Such statements, including statements regarding clinical
trials, out-licensing arrangements (including the timing and amount of
contingent payments), forecasts of future operating results, potential
collaborations, and capital raising activities, involve significant risks and
uncertainties and actual results could differ materially from those expressed
or implied herein. Factors that could cause such differences include, but are
not limited to, risks associated with any cash payment that the Company might
receive in connection with a sublicense involving a third party and UCB, which
is not within the Company's control, new product development (including
clinical trials outcome and regulatory requirements/actions), our dependence
on UCB for the further development of epratuzumab for non-cancer indications,
competitive risks to marketed products and availability of required financing
and other sources of funds on acceptable terms, if at all, as well as the
risks discussed in the Company's filings with the Securities and Exchange
Commission.The Company is not under any obligation, and the Company expressly
disclaims any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise.

CONTACT: For More Information:
         Dr. Chau Cheng
         Senior Director, Investor Relations & Grant Management
         (973) 605-8200, extension 123
Press spacebar to pause and continue. Press esc to stop.